Long-Acting Naltrexone for Pre-Release Prisoners
common.study.values.description
“Long-acting Naltrexone for Pre-release Prisoners”
This proposed five-year study will focus on whether the addition of providing XR-NTX treatment at a patients' place of residence will increase adherence and thus efficacy of the medication.Following initial screening, informed consent, and medical examination, pre-release prisoners at each facility will be block randomized (N=240) within gender to either: Condition 1. XR-NTX-OTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at an opioid treatment program; or Condition 2. XR-NTX+MMTx (n=120): One injection of XR-NTX in prison, followed by six monthly injections post-release in the community at the patient's place of residence.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - XR-NTX
Vivitrol
place of residence
One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
opioid treatment program
One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
participant.views.study.view.additional
participant.views.study.view.scientific-title
Long-acting Naltrexone for Pre-release Prisoners: A Randomized Trial of Mobile Treatment
common.study.values.clinical-trial-id
NCT02867124
participant.views.study.view.id
9av55e
